Whole-genome fetal and maternal DNA methylation analysis using MeDIP-NGS for the identification of differentially methylated regions
Date
2016Author
Keravnou, AnnaIoannides, Marios
Tsangaras, Kyriakos
Loizides, Charalambos
Hadjidaniel, Michael D.
Papageorgiou, Elisavet A.
Kyriakou, Skevi
Antoniou, Pavlos
Mina, Petros
Achilleos, Achilleas P.
Neofytou, Maria C.
Kypri, Elena
Sismani, Carolina
Koumbaris, George L.
Patsalis, Philippos C.
ISSN
1469-5073Source
Genetics ResearchVolume
98Pages
e15-e15Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
DNA methylation is an epigenetic marker that has been shown to vary significantly across different tissues. Taking advantage of the methylation differences between placenta-derived cell-free DNA and maternal blood, several groups employed different approaches for the discovery of fetal-specific biomarkers. The aim of this study was to analyse whole-genome fetal and maternal methylomes in order to identify and confirm the presence of differentially methylated regions (DMRs). We have initially utilized methylated DNA immunoprecipitation (MeDIP) and next-generation sequencing (NGS) to identify genome-wide DMRs between chorionic villus sampling (CVS) and female non-pregnant plasma (PL) and peripheral blood (WBF) samples. Next, using specific criteria, 331 fetal-specific DMRs were selected and confirmed in eight CVS, eight WBF and eight PL samples by combining MeDIP and in-solution targeted enrichment followed by NGS. Results showed higher enrichment in CVS samples as compared to both WBF and PL samples, confirming the distinct methylation levels between fetal and maternal DNA for the selected DMRs. We have successfully implemented a novel approach for the discovery and confirmation of a significant number of fetal-specific DMRs by combining for the first time MeDIP and in-solution targeted enrichment followed by NGS. The implementation of this double-enrichment approach is highly efficient and enables the detailed analysis of multiple DMRs by targeted NGS. Also, this is, to our knowledge, the first reported application of MeDIP on plasma samples, which leverages the implementation of our enrichment methodology in the detection of fetal abnormalities in maternal plasma.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors
Azim, Hatem A.; Pavlidis, Nicholas; Peccatori, Fedro A. (2010)Managing pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to ...
-
Article
Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?
Pavlidis, Nicholas (2011)The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...
-
Article
The pregnant mother with breast cancer: Diagnostic and therapeutic management
Pavlidis, Nicholas; Pentheroudakis, George (2005)This review describes the epidemiology, pathology, clinical picture and therapeutic management of pregnant women with breast cancer. In addition, it covers other important issues like the safety of both diagnostic and ...